Ceftazidime/Avibactam IV | Right Decisions

Right Decisions
Antimicrobial prescribing: NHS Grampian, Orkney & Shetland
Back
Protected (Alert) Policy
Ceftazidime/Avibactam IV

Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Permitted indications

Adults, adolescents and children aged 3 months and older for the treatment of the following infections:

complicated intra-abdominal infection (cIAI)
complicated urinary tract infection (cUTI), including pyelonephritis
hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)
infections due to aerobic Gram-negative organisms in patients with limited treatment options

For the treatment of severe drug-resistant infections caused by gram-negative bacteria, including, but not limited to, infections caused by OXA-48 carbapenemase-producing Enterobacterales:

only on the advice of a Consultant/Specialist Microbiologist or infectious disease specialist and,
only if the infection is susceptible to ceftazidime/avibactam and not susceptible to other suitable antibiotics; or if susceptibility results are not available but the infection needs urgent treatment and is expected to be susceptible to ceftazidime/avibactam but not to other suitable antibiotics